<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide is an important contemporary treatment option for patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="1" pm="."><plain>Rare instances of autoimmune conditions have been observed in association with its use </plain></SENT>
<SENT sid="2" pm="."><plain>Although moderate <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> is not uncommonly seen in patients treated with lenalidomide, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> has not previously been reported to be associated with this agent </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a case of severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) that was probably induced by lenalidomide </plain></SENT>
<SENT sid="4" pm="."><plain>A 64-year-old male patient developed progressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> three weeks into therapy with lenalidomide for his relapsed MM </plain></SENT>
<SENT sid="5" pm="."><plain>A bone marrow aspirate and biopsy confirmed the diagnosis of AA and suggested the existence of an immunological reaction at the level of marrow </plain></SENT>
<SENT sid="6" pm="."><plain>A gradual spontaneous recovery of <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis followed after the lenalidomide discontinuation </plain></SENT>
</text></document>